Aarti Drugs Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Aarti Drugs Ltd filed with BSE on 07 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Aarti Drugs reported Q1 FY27 consolidated revenue of Rs 703.6 crores, up 19% year-on-year, with EBITDA growing 30% to Rs 96.9 crores and EBITDA margin at 13.8%. Management attributed the growth to improved API realizations amid geopolitical disruptions in West Asia along with steady volume growth across API and Specialty Chemicals segments. The company also discussed progress on its Sayakha facility ramp-up, Metformin capacity expansion plans, and regulatory approvals across its API and formulations businesses.
Numbers mentioned
Revenue: INR703.6 crores (Q1 FY27)
p. 5
“Q1 FY27 revenue stood at INR703.6 crores compared to INR590.8 crores in Q1 FY26, reflecting a growth of 19% year-on-year.”
Adhish Patil, page 5 of the filed PDF · View the filing
EBITDA: INR96.9 crores (Q1 FY27)
p. 5
“EBITDA stood at INR96.9 crores versus INR74.4 crores in Q1 FY26, a growth of 30% year-on-year.”
Adhish Patil, page 5 of the filed PDF · View the filing
EBITDA margin: 13.8% (Q1 FY27)
p. 5
“EBITDA margin stood at 13.8%, an expansion of 120 basis points year-on-year.”
Adhish Patil, page 5 of the filed PDF · View the filing
PBT: INR69.2 crores (Q1 FY27)
p. 5
“PBT stood at INR69.2 crores as against INR51.1 crores, a growth of 35% year-on-year.”
Adhish Patil, page 5 of the filed PDF · View the filing
PBT margin: 9.9% (Q1 FY27)
p. 5
“PBT margin stood at 9.9% an expansion of 120 basis points year-on-year.”
Adhish Patil, page 5 of the filed PDF · View the filing
PAT: INR50.1 crores (Q1 FY27)
p. 5
“PAT stood at INR50.1 crores as compared to INR54.0 crores in Q1 FY26.”
Adhish Patil, page 5 of the filed PDF · View the filing
Stand-alone revenue: INR627.6 crores (Q1 FY27)
p. 5
“With respect to the stand-alone business highlights in Q1 FY27, revenue stood at INR627.6 crores versus INR521.3 crores in Q1 FY26, a growth of 20% year-on-year.”
Adhish Patil, page 5 of the filed PDF · View the filing
Formulations revenue: INR81.6 crores (Q1 FY27)
p. 5
“Revenue from formulations stood at INR81.6 crores compared to INR75.8 crores in Q1 FY26, up 8% year-on-year.”
Adhish Patil, page 5 of the filed PDF · View the filing
Sayakha facility utilization: nearly 65% (Q1 FY27)
p. 4
“During Q1 FY27, our Sayakha facility continued its planned ramp-up and operated at nearly 65% utilization.”
Adhish Patil, page 4 of the filed PDF · View the filing
Aggregate volume growth: 3.5% (Q1 FY27)
p. 10
“Overall company level, we still achieved around 3.5% aggregate volume growth both domestic and local markets.”
Adhish Patil, page 10 of the filed PDF · View the filing
Aggregate price growth: 16%-17% (Q1 FY27 vs Q1 FY26)
p. 10
“In Y-o-Y basis, at the aggregate level, we saw somewhere around 16%, 17% aggregate growth.”
Adhish Patil, page 10 of the filed PDF · View the filing
Salicylic acid production: 67 tons (Q1 FY27)
p. 9
“In fact, in the entire quarter we produced only 67 tons of salicylic acid.”
Adhish Patil, page 9 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin — 15%
stated as an aspiration by Adhish Patil
p. 11
“Now once the utilization of the two main greenfield projects what we have put up once that improves, then definitely 15% should be very easy.”
Adhish Patil, page 11 of the filed PDF · View the filing
Volume growth — 10% to 15% · next two years
stated conditionally by Adhish Patil
p. 11
“So the thing is for next two years, we are very well poised for that 10% to 15% kind of a volume growth”
Adhish Patil, page 11 of the filed PDF · View the filing
Metformin capacity — roughly around 2,200 tons per month
stated firmly by Adhish Patil
p. 6
“So our current plan is to scale up Metformin from 1,400 tons per month to roughly around 2,200 tons per month, out of which around 500-550 tons per month would be a USFDA capacity and the rest of the capacity would be for the other non-USFDA markets.”
Adhish Patil, page 6 of the filed PDF · View the filing
USFDA Metformin capacity commissioning — 10 to 12 months
stated firmly by Adhish Patil
p. 6
“But the thing is because we are constructing a fresh roughly 500+ tons per month capacity in the same location, so it will take roughly around 10 to 12 months for that capacity to come up, and immediately as it comes up, we will file for the USFDA inspection with the help of some customer.”
Adhish Patil, page 6 of the filed PDF · View the filing
Captive consumption from Sayakha — 80%, 90% · September quarter and December quarter
stated as an aspiration by Adhish Patil
p. 13
“So increasingly in September quarter and then by December quarter, I think hopefully around 80%, 90% of the captive consumption will happen through Sayakha plant.”
Adhish Patil, page 13 of the filed PDF · View the filing
Gross contribution improvement from Sayakha utilization — another 1% or so
stated as an aspiration by Adhish Patil
p. 13
“So, we are hoping that it should add another 1% or so in the gross contribution at the peak level.”
Adhish Patil, page 13 of the filed PDF · View the filing
Baddi facility expansion — nearly double our oral solid dosage manufacturing capacity
stated firmly by Adhish Patil
p. 4
“Once completed, this project is expected to nearly double our oral solid dosage manufacturing capacity.”
Adhish Patil, page 4 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said metformin prices rose 15-20% compared to before the war, with the major hike coming around March-April, now slightly lower than that peak.
Answered by Harit Shah
Asked by Avnish Burman: How has metformin pricing moved quarter-on-quarter and year-on-year?
p. 6
“Yes, pricing movement. Yes, it has gone up by around 15%, 20% compared to before the war, 20% approximately.”
Harit Shah, page 6 of the filed PDF · View the filing
Management said the US DMF is already filed but the new USFDA capacity will take about 10-12 months to come online before inspection can be filed.
Answered by Adhish Patil
Asked by Avnish Burman: When can supply to the US market for metformin begin?
p. 6
“Yes, the US DMF we have already filed, so that is not a challenge. But the thing is because we are constructing a fresh roughly 500+ tons per month capacity in the same location, so it will take roughly around 10 to 12 months for that capacity to come up, and immediately as it comes up, we will file for the USFDA inspection with the help of some customer.”
Adhish Patil, page 6 of the filed PDF · View the filing
Management said conditions remain volatile and it is too early to confirm a sustained recovery, though the business remains stable versus Chinese competition.
Answered by Adhish Patil
Asked by Parth Sodha: Has the API industry entered a sustained recovery phase?
p. 7
“But again, things are quite volatile as of now to say anything.”
Adhish Patil, page 7 of the filed PDF · View the filing
Management said Phase 1 greenfield facilities have an asset turn of around 1.5x, while Phase 2 brownfield capex should generate higher turns of 3x-4x.
Answered by Adhish Patil
Asked by Parth Sodha: What is the expected asset turnover from the recent capex?
p. 7
“Yes. So, the asset turn from the Phase 1 greenfield facilities is around 1.5x, roughly.”
Adhish Patil, page 7 of the filed PDF · View the filing
Management said the plant currently supplies sedative, antibiotic and anti-inflammatory products mainly to Europe, with US supply pending vendor approval after sample submission.
Answered by Adhish Patil
Asked by Rashmi Shetty: What is the update on the E-22 USFDA plant and which markets are being supplied?
p. 8
“Correct. Yes. So, the U.S. market hasn't started yet, but the business development has already started the sample approval.”
Adhish Patil, page 8 of the filed PDF · View the filing
Management said production was kept low while awaiting new equipment, and the anti-dumping duty decision has been delayed by about a year, so they will focus on salicylate derivatives in the interim.
Answered by Adhish Patil
Asked by Rashmi Shetty: What is the status of salicylic acid production and the anti-dumping duty case at Tarapur?
p. 9
“So we'll have to wait most probably 1 more year for anti-dumping duty to come up.”
Adhish Patil, page 9 of the filed PDF · View the filing
Management said most growth came from price increases due to raw material cost hikes from the war, and that pricing pressure may ease once raw material costs decline.
Answered by Adhish Patil
Asked by Rashmi Shetty: What drove volume versus price growth this quarter, and is the pricing sustainable?
p. 10
“Right now, again, the pressure is still there. But as the war, everything eases out, then when the raw material prices goes down, then probably the selling prices will come down.”
Adhish Patil, page 10 of the filed PDF · View the filing
Management said they had already crossed 14% EBITDA margin in Q1 and believe 15% is achievable as utilization of greenfield projects improves.
Answered by Adhish Patil
Asked by Dhwanil Desai: Is 15% EBITDA margin achievable once realizations normalize?
p. 11
“Yes. So Dhwanil, this quarter also we took some write-offs of aging Capital WIP, but that way, we had crossed around 14% EBITDA margin in Q1 as well, at consolidated level.”
Adhish Patil, page 11 of the filed PDF · View the filing
Management said 10% volume growth should still be doable even in that scenario.
Answered by Adhish Patil
Asked by Dhwanil Desai: Is 10-15% volume growth achievable given recent capex, even without the salicylic acid derivative ramp-up?
p. 12
“Yes. Still 10% should be doable.”
Adhish Patil, page 12 of the filed PDF · View the filing
Management said around 60-70% was still procured externally last quarter, but that percentage has already declined and captive consumption should rise sharply going forward.
Answered by Adhish Patil
Asked by Sajal Kapoor: How much of Sayakha's benefit is currently reflected in revenue versus hidden through replaced external procurement?
p. 13
“Yes. So I would say, the last quarter still around 60%, 70% we must have procured from outside, last quarter, in the June quarter.”
Adhish Patil, page 13 of the filed PDF · View the filing
Risks flagged
Geopolitical conflict in West Asia affecting trade, logistics and supply chains
p. 3
“Geopolitical developments, particularly the ongoing conflict in West Asia, remained an important factor affecting international trade, logistics, and supply chains.”
Adhish Patil, page 3 of the filed PDF · View the filing
Elevated freight costs and raw material price volatility
p. 3
“The industry also continued to witness elevated freight costs on certain routes, longer procurement cycles in a few regions, and increased volatility in raw material pricing.”
Adhish Patil, page 3 of the filed PDF · View the filing
Demand pressure in domestic formulations when prices are very high
p. 11
“as in three, four years back, that in the very high prices scenario, certain categories of products, like, mostly antibiotics and antidiarrheals, they faced demand pressure.”
Adhish Patil, page 11 of the filed PDF · View the filing
Delay in anti-dumping duty on salicylic acid
p. 9
“Unfortunately, what has happened to the anti-dumping duty part, it got delayed a little bit.”
Adhish Patil, page 9 of the filed PDF · View the filing
Chinese competitors dropping salicylic acid prices to undercut competition
p. 10
“But then after we launched the capacity, Chinese players, they drastically dropped the pricing of salicylic acid, mainly to drive the competition out.”
Adhish Patil, page 10 of the filed PDF · View the filing
Ammonia and derivative compound shortages affecting input prices
p. 13
“in the current condition, yes, but then what happened in June quarter was because of that ammonia shortages and the derivative compound shortages, the prices have gone up quite drastically for this chain of products.”
Adhish Patil, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.